172@29@17@144!~!172@29@0@53!~!|news|business|unichem-laboratories-gets-usfda-nod-to-market-muscle-spasm-tablets-5519071.html!~!|controller|infinite_scroll_article.php

Network18 Presents

partnered by

  • Galaxy Note20 | 20 Ultra
Moneycontrol
Financial Freedom Offer: Subscribe to Moneycontrol Pro and grab benefits worth ₹15,000/-

Network18 Presents

  • partnered by
  • Galaxy Note20 | 20 Ultra
you are here: HomeNewsBusiness
Last Updated : Jul 07, 2020 07:50 PM IST | Source: PTI

Unichem Laboratories gets USFDA nod to market muscle spasm tablets

The company has received abbreviated new drug application (ANDA) approval to market its Cyclobenzaprine Hydrochloride tablets USP 5 mg, 7.5 mg and 10 mg from the United States Food and Drug Administration (USFDA), Unichem Labs said in a filing to the BSE.

PTI
Representative image
Representative image
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Drug firm Unichem Laboratories on Tuesday said it has received approval from the US health regulator to market its Cyclobenzaprine Hydrochloride tablets used for relief of muscle spasm in the American market.

The company has received abbreviated new drug application (ANDA) approval to market its Cyclobenzaprine Hydrochloride tablets USP 5 mg, 7.5 mg and 10 mg from the United States Food and Drug Administration (USFDA), Unichem Labs said in a filing to the BSE.

The product is a generic version of Janssen Research and Development LLC's Flexeril tablets, it added.

Close

The tablets will be commercialised from the company's Goa plant, Unichem Labs said.

Cyclobenzaprine Hydrochloride tablets are indicated for the treatment as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions, it added.

Shares of Unichem Labs on Tuesday closed 3.33 percent higher at Rs 189.10 per scrip on the BSE.
First Published on Jul 7, 2020 07:41 pm
Sections